Pay in 4 interest-free payments of $5.92 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
The payoff
(Nasdaq: GUTS) (the Company or Fractyl), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced groundbreaking results from the REMAIN-1 Midpoint Cohort, supporting the potential for Revita to be the first therapy to preserve weight loss after GLP-1 drug discontinuation
What matters most is finding the dose that works best for you, balancing comfort, results, and your personal health goals
Heres the honest truthwhat is covered now, potential changes, what GLP-1s do, the pros & cons, and why for many, diet + exercise are still powerful, safer tools
US$ 26.62
US$ 25.08
US$ 29.93
US$ 25.91
US$ 27.61
US$ 26.52
US$ 26.79
US$ 26.45
